Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
Earnings Data
Report Date
Aug 11, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-1.05Last Year’s EPS
-1.67Same Quarter Last Year
Strong Buy
Based on 18 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 05, 2025
|% Change Since: 3.81%
|Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with strong revenue growth, successful product launches, and significant pipeline advancements. However, the company faces challenges in achieving profitability and navigating regulatory and market landscapes.Company Guidance
In the Axsome Therapeutics First Quarter 2025 Conference Call, the company reported a strong performance with a 62% year-over-year increase in total revenue, attributed mainly to the demand for Auvelity and Sunosi. The recent FDA approval of Symbravo was highlighted as a significant milestone. Key pipeline priorities were discussed, including advancing three novel NDA-stage product candidates: AXS-14 for fibromyalgia, AXS-05 for Alzheimer's disease agitation, and AXS-12 for cataplexy and narcolepsy. The company successfully submitted the NDA for AXS-14 and plans to submit the sNDA for AXS-05 in the third quarter, with a potential launch in 2026. Several Phase III trials are underway, including Solriamfetol for ADHD, MDD, binge eating disorder, and excessive sleepiness related to shift work disorder. Financially, Axsome reported $121.5 million in total product revenues for the quarter, with net product sales of $120.4 million. The company ended Q1 2025 with $300.9 million in cash and cash equivalents and expressed confidence in reaching cash flow positivity with its current resources.Significant Revenue Growth
Axsome Therapeutics reported a year-over-year total revenue growth of 62% for the first quarter of 2025, with total product revenues reaching $121.5 million.
Successful Product Launch and FDA Approval
The FDA approved Symbravo, Axsome's second internally developed product, marking a significant achievement in expanding their product portfolio.
Strong Performance of Key Products
Auvelity achieved an 80% year-over-year growth in net product sales, reaching $96.2 million in the first quarter of 2025.
Pipeline Advancements
Axsome submitted an NDA for AXS-14 for fibromyalgia and plans to submit an sNDA for AXS-05 for Alzheimer's disease agitation in the third quarter of 2025.
Expansion in Clinical Programs
Announced positive top-line results from Phase III trials for Solriamfetol in ADHD and Symbravo in migraine, paving the way for further trials and potential market expansion.
---
AXSM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AXSM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 05, 2025 | $112.21 | $116.49 | +3.81% |
| Feb 18, 2025 | $131.15 | $128.09 | -2.33% |
| Nov 12, 2024 | $90.98 | $99.49 | +9.35% |
| Aug 05, 2024 | $84.42 | $83.21 | -1.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Axsome Therapeutics Inc (AXSM) report earnings?
Axsome Therapeutics Inc (AXSM) is schdueled to report earning on Aug 11, 2025, TBA Not Confirmed.
What is Axsome Therapeutics Inc (AXSM) earnings time?
Axsome Therapeutics Inc (AXSM) earnings time is at Aug 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AXSM EPS forecast?
AXSM EPS forecast for the fiscal quarter 2025 (Q2) is -1.05.
---